Soluble CD40L Versus Myocyte Enhancer Factor: Predicting a Prominent Marker For Cardiovascular Disease

Atherosclerosis (ACS) has set off the innovation of molecular markers measured in plasma or serum, and used for the identification of individuals at high risk of Coronary Heart Disease (CHD). In an attempt to improve cardiovascular risk prediction, considerable interest is focused on inflammatory biomarkers including Interleukin (IL)-6, Phospholamban (PLB), Myocyte enhancer factor 2A (MEF2A), and Soluble CD40 ligand. In this paper, signal-processing techniques predicted the characteristic frequencies of the above-mentioned proteins, and common binding sites. The CD40L characteristic frequency, 0.3555 ± 0.0001, is correlated with Protease inhibitors and the second peak, 0.4531 ± 0.0009, is closely related to Fgfs. This study also revealed that for MEF2A, the characteristic frequency, 0.0488 ± 0.0001, is specific for enhancers DNA regulating sequences. The remaining frequencies, 0.3672 ± 0.0001 and 0.4648 ± 0.0002, are characteristic of the Myocyte Protease inhibiting activity and SOS operator function. Furthermore, clinical data suggested that the increased levels of CD40L reliably identify the subgroup of patients with ACS who are at highest risk for cardiac events. It is suggested that CD40L is a most prominent candidate for early detection of cardiac disease.